Related Experiment Video
Updated: Aug 24, 2026
Orthotopic Implantation of Patient-Derived Cancer Cells in Mice Recapitulates Advanced Colorectal Cancer
Published on: February 10, 2023
A pilot phase II study of capecitabine in advanced or recurrent colorectal cancer
Yukifumi Kondo1, Masanori Terashima, Atsushi Sato
1Department of Surgery, Sapporo-Kosei General Hospital, Kita-3, Higashi-8, Chuo-ku, Sapporo, Hokkaido 060-0033, Japan. yuki.kondou@ja-hokkaidoukouseiren.or.jp
Background:
A pilot phase II study was conducted to evaluate the Japanese intermittent regimen of capecitabine in patients with advanced/recurrent colorectal cancer.
Methods:
Twenty-two patients received oral capecitabine in a dose of 828 mg/m(2) twice daily for 3 weeks every 4 weeks.
Results:
In the 20 patients evaluable for efficacy, the overall response rate was 25.0% (95% CI, 8.7-49.1%), rising to 33.0% in the subset of patients previously untreated for metastatic disease (n = 9). A further nine patients had stable disease. The median duration of response was 7.0 months. Five patients (22.7%) experienced grade 3/4 treatment-related adverse events, the most common being a bullous rash observed in two patients (9.1%).
Conclusions:
The 3 weeks out of 4 intermittent regimen of capecitabine demonstrated good antitumor activity and tolerability in patients with advanced/refractory colorectal cancer, providing a clear rationale for conducting a larger phase II study in patients with advanced disease.
